Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

Vertex is focused on discovering, developing and producing innovative medicines so people with serious diseases can lead better lives. Our scientists don’t see the impossible as an obstacle; they see it as a good place to start.

Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.

The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

At Vertex, the world’s most talented and passionate people come together to advance science and transform lives, and in return, we invest in them so they can grow and advance their own careers. If you’re ready to join us, browse open positions below.

Vertex Pharmaceuticals has research and development sites, manufacturing facilities, headquarters and regional offices around the world.

Mar 31, 2024 · Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion. Vertex’s product revenue guidance includes expectations for continued growth in CF as well as for the launch of CASGEVY in approved indications and geographies.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people living with serious diseases, with a focus on specialty markets.

6 days ago · Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain -- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years --

BOSTON --(BUSINESS WIRE)--Jan. 17, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2023 financial results on Monday, February 5, 2024 after the financial markets close. The company will host a …